Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles Fisher

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
American Journal of Industrial Medicine|June 25, 2013
Beryllium disease among construction trade workers at Department of Energy nuclear sitesLaura S Welch, Knut Ringen, John Dement, et al.
The Lancet. Diabetes & Endocrinology|August 16, 2015
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysisMiles Fisher, Mark C Petrie, Philip D Ambery, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 20, 2024
Diagnostic delay in monogenic disease: A scoping reviewRory J Tinker, Miles Fisher, Alex F Gimeno, et al.
Diabetes, Obesity & Metabolism|August 31, 2018
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimenGeremia B Bolli, Carol Wysham, Miles Fisher, et al.
Journal of Shoulder and Elbow Surgery|December 7, 2007
Prevalence of symptoms and signs of shoulder problems in people with diabetes mellitusSimon J Thomas, Claire McDougall, Iain D M Brown, et al.
Diabetes, Obesity & Metabolism|July 25, 2017
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)Ronan Roussel, Michael C d'Emden, Miles Fisher, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trialDavid Preiss, Suzanne M Lloyd, Ian Ford, et al.
European Heart Journal|April 22, 2008
Diabetes, left ventricular systolic dysfunction, and chronic heart failureMichael R MacDonald, Mark C Petrie, Nathaniel M Hawkins, et al.
American Journal of Industrial Medicine|January 7, 2026
Impact of Secondary Prevention on Mortality in the Building Trades National Medical Screening Program: Effectiveness of Occupational High-Risk ManagementKnut Ringen, John M Dement, Marianne Cloeren, et al.
Lancet (London, England)|April 24, 2012
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialSimon Heller, John Buse, Miles Fisher, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
American Journal of Industrial Medicine|June 25, 2013
Beryllium disease among construction trade workers at Department of Energy nuclear sitesLaura S Welch, Knut Ringen, John Dement, et al.
The Lancet. Diabetes & Endocrinology|August 16, 2015
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysisMiles Fisher, Mark C Petrie, Philip D Ambery, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 20, 2024
Diagnostic delay in monogenic disease: A scoping reviewRory J Tinker, Miles Fisher, Alex F Gimeno, et al.
Diabetes, Obesity & Metabolism|August 31, 2018
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimenGeremia B Bolli, Carol Wysham, Miles Fisher, et al.
Journal of Shoulder and Elbow Surgery|December 7, 2007
Prevalence of symptoms and signs of shoulder problems in people with diabetes mellitusSimon J Thomas, Claire McDougall, Iain D M Brown, et al.
Diabetes, Obesity & Metabolism|July 25, 2017
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)Ronan Roussel, Michael C d'Emden, Miles Fisher, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trialDavid Preiss, Suzanne M Lloyd, Ian Ford, et al.
European Heart Journal|April 22, 2008
Diabetes, left ventricular systolic dysfunction, and chronic heart failureMichael R MacDonald, Mark C Petrie, Nathaniel M Hawkins, et al.
American Journal of Industrial Medicine|January 7, 2026
Impact of Secondary Prevention on Mortality in the Building Trades National Medical Screening Program: Effectiveness of Occupational High-Risk ManagementKnut Ringen, John M Dement, Marianne Cloeren, et al.
Lancet (London, England)|April 24, 2012
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trialSimon Heller, John Buse, Miles Fisher, et al.
Pageof 3